AQR Capital Management LLC lowered its stake in Cambrex Corporation (NYSE:CBM) by 12.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 84,923 shares of the biotechnology company’s stock after selling 11,715 shares during the period. AQR Capital Management LLC’s holdings in Cambrex Corporation were worth $4,675,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in CBM. Flinton Capital Management LLC boosted its stake in shares of Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 68 shares during the period. State of Alaska Department of Revenue boosted its position in shares of Cambrex Corporation by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 3,570 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 90 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Cambrex Corporation by 1.3% in the first quarter. Municipal Employees Retirement System of Michigan now owns 9,080 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 120 shares during the last quarter. Capital One National Association boosted its position in shares of Cambrex Corporation by 1.1% in the first quarter. Capital One National Association now owns 14,765 shares of the biotechnology company’s stock valued at $813,000 after buying an additional 156 shares during the last quarter. Finally, Sawtooth Solutions LLC boosted its position in shares of Cambrex Corporation by 3.6% in the first quarter. Sawtooth Solutions LLC now owns 7,243 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 254 shares during the last quarter.

Cambrex Corporation (NYSE:CBM) opened at 58.05 on Wednesday. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95. The stock’s 50 day moving average is $57.93 and its 200 day moving average is $55.08. The firm has a market cap of $1.89 billion, a PE ratio of 22.10 and a beta of 2.28.

Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.17. The business had revenue of $105.01 million for the quarter, compared to analyst estimates of $99.05 million. Cambrex Corporation had a return on equity of 24.92% and a net margin of 17.36%. During the same quarter last year, the company earned $0.50 earnings per share. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities analysts forecast that Cambrex Corporation will post $3.02 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Cambrex Corporation (CBM) Stake Decreased by AQR Capital Management LLC” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/cambrex-corporation-cbm-stake-decreased-by-aqr-capital-management-llc/1451545.html.

CBM has been the topic of several recent research reports. Zacks Investment Research raised shares of Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research report on Thursday, May 11th. ValuEngine cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, BidaskClub raised shares of Cambrex Corporation from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Cambrex Corporation has a consensus rating of “Buy” and an average target price of $64.00.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $59.66, for a total value of $715,920.00. Following the sale, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $5,687,268.48. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Leon J. Hendrix, Jr. sold 20,656 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $55.95, for a total value of $1,155,703.20. Following the completion of the sale, the director now directly owns 74,662 shares in the company, valued at $4,177,338.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 70,656 shares of company stock worth $4,026,143. 2.48% of the stock is owned by corporate insiders.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.